338 related articles for article (PubMed ID: 35169082)
41. ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis.
Wiestler B; Capper D; Holland-Letz T; Korshunov A; von Deimling A; Pfister SM; Platten M; Weller M; Wick W
Acta Neuropathol; 2013 Sep; 126(3):443-51. PubMed ID: 23904111
[TBL] [Abstract][Full Text] [Related]
42. The Place and Prognostic Value of TERT Promoter Mutation in Molecular Classification in Grade II-III Glial Tumors and Primary Glioblastomas.
Terzi NK; Yilmaz I; Oz AB
Turk Patoloji Derg; 2022; 38(2):90-98. PubMed ID: 34558656
[TBL] [Abstract][Full Text] [Related]
43. Genomic profiles of IDH-mutant gliomas: MYCN-amplified IDH-mutant astrocytoma had the worst prognosis.
Lee K; Kim SI; Kim EE; Shim YM; Won JK; Park CK; Choi SH; Yun H; Lee H; Park SH
Sci Rep; 2023 Apr; 13(1):6761. PubMed ID: 37185778
[TBL] [Abstract][Full Text] [Related]
44. IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas.
Leeper HE; Caron AA; Decker PA; Jenkins RB; Lachance DH; Giannini C
Oncotarget; 2015 Oct; 6(30):30295-305. PubMed ID: 26210286
[TBL] [Abstract][Full Text] [Related]
45. Prediction of
Park YW; Han K; Ahn SS; Bae S; Choi YS; Chang JH; Kim SH; Kang SG; Lee SK
AJNR Am J Neuroradiol; 2018 Jan; 39(1):37-42. PubMed ID: 29122763
[TBL] [Abstract][Full Text] [Related]
46. Evaluation of MTAP and p16 immunohistochemical deficiency as surrogate marker for CDKN2A/B homozygous deletion in gliomas.
Maragkou T; Reinhard S; Jungo P; Pasquier B; Neuenschwander M; Schucht P; Vassella E; Hewer E
Pathology; 2023 Jun; 55(4):466-477. PubMed ID: 37032198
[TBL] [Abstract][Full Text] [Related]
47. Molecular Genetic Profile of 300 Japanese Patients with Diffuse Gliomas Using a Glioma-tailored Gene Panel.
Higa N; Akahane T; Yokoyama S; Yonezawa H; Uchida H; Fujio S; Kirishima M; Takigawa K; Hata N; Toh K; Yamamoto J; Hanaya R; Tanimoto A; Yoshimoto K
Neurol Med Chir (Tokyo); 2022 Sep; 62(9):391-399. PubMed ID: 36031351
[TBL] [Abstract][Full Text] [Related]
48. IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma.
Zhang C; Moore LM; Li X; Yung WK; Zhang W
Neuro Oncol; 2013 Sep; 15(9):1114-26. PubMed ID: 23877318
[TBL] [Abstract][Full Text] [Related]
49. Diffuse gliomas in patients aged 55 years or over: A suggestion for IDH mutation testing.
Barresi V; Eccher A; Simbolo M; Cappellini R; Ricciardi GK; Calabria F; Cancedda M; Mazzarotto R; Bonetti B; Pinna G; Sala F; Ghimenton C; Scarpa A
Neuropathology; 2020 Feb; 40(1):68-74. PubMed ID: 31758617
[TBL] [Abstract][Full Text] [Related]
50. Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma.
Kannan K; Inagaki A; Silber J; Gorovets D; Zhang J; Kastenhuber ER; Heguy A; Petrini JH; Chan TA; Huse JT
Oncotarget; 2012 Oct; 3(10):1194-203. PubMed ID: 23104868
[TBL] [Abstract][Full Text] [Related]
51. 1p/19q co-deleted fibrillary astrocytomas: Not everything that is co-deleted is an oligodendroglioma.
Andrews C; Prayson RA
Ann Diagn Pathol; 2020 Jun; 46():151519. PubMed ID: 32305004
[TBL] [Abstract][Full Text] [Related]
52. A tailored next-generation sequencing panel identified distinct subtypes of wildtype IDH and TERT promoter glioblastomas.
Higa N; Akahane T; Yokoyama S; Yonezawa H; Uchida H; Takajo T; Kirishima M; Hamada T; Matsuo K; Fujio S; Hanada T; Hosoyama H; Yonenaga M; Sakamoto A; Hiraki T; Tanimoto A; Yoshimoto K
Cancer Sci; 2020 Oct; 111(10):3902-3911. PubMed ID: 32748499
[TBL] [Abstract][Full Text] [Related]
53. Novel, improved grading system(s) for IDH-mutant astrocytic gliomas.
Shirahata M; Ono T; Stichel D; Schrimpf D; Reuss DE; Sahm F; Koelsche C; Wefers A; Reinhardt A; Huang K; Sievers P; Shimizu H; Nanjo H; Kobayashi Y; Miyake Y; Suzuki T; Adachi JI; Mishima K; Sasaki A; Nishikawa R; Bewerunge-Hudler M; Ryzhova M; Absalyamova O; Golanov A; Sinn P; Platten M; Jungk C; Winkler F; Wick A; Hänggi D; Unterberg A; Pfister SM; Jones DTW; van den Bent M; Hegi M; French P; Baumert BG; Stupp R; Gorlia T; Weller M; Capper D; Korshunov A; Herold-Mende C; Wick W; Louis DN; von Deimling A
Acta Neuropathol; 2018 Jul; 136(1):153-166. PubMed ID: 29687258
[TBL] [Abstract][Full Text] [Related]
54. Static and dynamic
Verger A; Stoffels G; Bauer EK; Lohmann P; Blau T; Fink GR; Neumaier B; Shah NJ; Langen KJ; Galldiks N
Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):443-451. PubMed ID: 29043400
[TBL] [Abstract][Full Text] [Related]
55. Multi-parametric Z-spectral MRI may have a good performance for glioma stratification in clinical patients.
Su C; Xu S; Lin D; He H; Chen Z; Damen FC; Ke C; Lv X; Cai K
Eur Radiol; 2022 Jan; 32(1):101-111. PubMed ID: 34272981
[TBL] [Abstract][Full Text] [Related]
56. Microvascular characteristics of lower-grade diffuse gliomas: investigating vessel size imaging for differentiating grades and subtypes.
Guo H; Kang H; Tong H; Du X; Liu H; Tan Y; Yang Y; Wang S; Zhang W
Eur Radiol; 2019 Apr; 29(4):1893-1902. PubMed ID: 30276676
[TBL] [Abstract][Full Text] [Related]
57. Oligosarcomas, IDH-mutant are distinct and aggressive.
Suwala AK; Felix M; Friedel D; Stichel D; Schrimpf D; Hinz F; Hewer E; Schweizer L; Dohmen H; Pohl U; Staszewski O; Korshunov A; Stein M; Wongsurawat T; Cheunsuacchon P; Sathornsumetee S; Koelsche C; Turner C; Le Rhun E; Mühlebner A; Schucht P; Özduman K; Ono T; Shimizu H; Prinz M; Acker T; Herold-Mende C; Kessler T; Wick W; Capper D; Wesseling P; Sahm F; von Deimling A; Hartmann C; Reuss DE
Acta Neuropathol; 2022 Feb; 143(2):263-281. PubMed ID: 34967922
[TBL] [Abstract][Full Text] [Related]
58. Advanced imaging parameters improve the prediction of diffuse lower-grade gliomas subtype, IDH mutant with no 1p19q codeletion: added value to the T2/FLAIR mismatch sign.
Lee MK; Park JE; Jo Y; Park SY; Kim SJ; Kim HS
Eur Radiol; 2020 Feb; 30(2):844-854. PubMed ID: 31446467
[TBL] [Abstract][Full Text] [Related]
59. Correlating MRI features with additional genetic markers and patient survival in histological grade 2-3 IDH-mutant astrocytomas.
Lasocki A; Buckland ME; Molinaro T; Xie J; Whittle JR; Wei H; Gaillard F
Neuroradiology; 2023 Aug; 65(8):1215-1223. PubMed ID: 37316586
[TBL] [Abstract][Full Text] [Related]
60. Molecular pathogenesis of IDH mutations in gliomas.
Ichimura K
Brain Tumor Pathol; 2012 Jul; 29(3):131-9. PubMed ID: 22399191
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
